hero image

A statement about Biogen Political Action Committee

January 13, 2021 Company Statements
Following last week’s deeply concerning events in Washington DC, we are suspending all political donations to allow a thorough review of our political contribution criteria and policies. Biogen supports the rule of law and democratic process and calls for a peaceful transition of power.
thumb
November 17, 2021
Update on Regulatory Review of Aducanumab in the European Union

CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) announced today an update on the ongoing review of the Marketing Authorization Application for aducanumab 100 mg/mL concentrate solution for infusion for the treatment of Alzheimer’s

thumb
November 16, 2021
The European Commission Grants Marketing Authorization for VUMERITY® (diroximel fumarate) as Oral Treatment for Relapsing-Remitting Multiple Sclerosis

VUMERITY is a next-generation oral fumarate treatment for people with relapsing-remitting MS with established efficacy and well-characterized safety, building on Biogen’s leadership in MS oral therapies Phase 3 data have demonstrated that treatment with VUMERITY results in low discontinuation rates